Deke Medical Completes Tens of Millions RMB Series A Strategic Financing to Advance Hydrogel-Based Myocardial Repair Therapy for Heart Failure

News on February 18: Hangzhou Deke Medtech Co., Ltd. (hereinafter referred to as "Deke Medtech") has completed its first round of strategic financing. This round of financing amounts to tens of millions of RMB, exclusively invested by Tasly Capital. The funds will mainly be used to accelerate the research and development of innovative product pipelines and the progress of clinical trials, which is expected to expedite the application of hydrogel myocardial repair technology in the field of heart failure treatment.

Deke Medtech was registered and established in March 2017 in Binjiang District, Hangzhou, as an innovative medical device R&D enterprise incubated by DNO Medtech. It is committed to becoming a globally leading innovative pioneer in the clinical treatment of heart failure using hydrogel myocardial repair technology.